Literature DB >> 19777197

[Chronic inflammatory intestinal diseases. Pathophysiology and therapy].

K Herrlinger1, B Wittig, E F Stange.   

Abstract

The pathogenesis and therapy of chronic inflammatory intestinal diseases are characterized by an obvious discrepancy. There is extensive agreement that the pathogenesis is substantially based on a disruption of the barrier of the intestinal mucous membrane against luminal bacteria. This has been demonstrated in recent years by evidence from various disciplines, in particular from genetics, microbiology, morphology and innate immunology. However, there is also the evidence-based therapy which, as in the past, is aimed against the effectors of the adaptive immune system. In this case the therapy with biologicals is more aggressive and takes the risk of a series of undesired side-effects. This dichotomy of pathological knowledge and therapeutic innovation is not only medically unsatisfactory but also makes it difficult to present a consistent picture of these symptoms. Despite this an attempt will be made to bridge these inconsistencies and to demonstrate possible future developments which will lead to a final causal therapy. An extended version of this article appears in our newly published book "Colitis ulcerosa und Morbus Crohn".

Entities:  

Mesh:

Year:  2009        PMID: 19777197     DOI: 10.1007/s00108-009-2485-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  36 in total

Review 1.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  L Sutherland; J K Macdonald
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

Authors:  S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

3.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

Authors:  Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Journal:  Lancet       Date:  2008-02-23       Impact factor: 79.321

4.  Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.

Authors:  P Marteau; C S Probert; S Lindgren; M Gassul; T G Tan; A Dignass; R Befrits; G Midhagen; J Rademaker; M Foldager
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

5.  Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis.

Authors:  W Stremmel; U Merle; A Zahn; F Autschbach; U Hinz; R Ehehalt
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

6.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

7.  A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon.

Authors:  Klaus Fellermann; Daniel E Stange; Elke Schaeffeler; Hartmut Schmalzl; Jan Wehkamp; Charles L Bevins; Walter Reinisch; Alexander Teml; Matthias Schwab; Peter Lichter; Bernhard Radlwimmer; Eduard F Stange
Journal:  Am J Hum Genet       Date:  2006-07-12       Impact factor: 11.025

8.  Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.

Authors:  C Cammà; M Giunta; M Rosselli; M Cottone
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

9.  IL-23 promotes maintenance but not commitment to the Th17 lineage.

Authors:  Gretta L Stritesky; Norman Yeh; Mark H Kaplan
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

Review 10.  Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.

Authors:  Eliza Prefontaine; Lloyd R Sutherland; John K Macdonald; Monica Cepoiu
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
View more
  2 in total

1.  [New therapeutic approaches to special diseases of the small intestine].

Authors:  M Schumann; K Herrlinger; M Zeitz; E F Stange
Journal:  Internist (Berl)       Date:  2010-06       Impact factor: 0.743

Review 2.  [What has been confirmed in the treatment of inflammatory bowel disease?].

Authors:  B Siegmund; J C Preiss; M Zeitz
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.